Correlation between some Biomarker Levels and Disease Activity in Patients with Systemic Lupus Erythematosus | ||
| Egyptian Journal of Medical Microbiology | ||
| Articles in Press, Accepted Manuscript, Available Online from 01 April 2026 | ||
| Document Type: New and original researches in the field of Microbiology. | ||
| DOI: 10.21608/ejmm.2025.416914.1839 | ||
| Authors | ||
| Noor Al-huda Zamil* 1; Mayada N. Iqbal1; Nisreen S. Alyasiri2 | ||
| 1Department of Medical Laboratory Techniques, College of Health and Medical Technology, Baghdad, Middle Technical University, Baghdad, Iraq | ||
| 2Department of Medical Laboratory Techniques, Suwaira Technical Institute, Middle Technical University, Waist, Iraq | ||
| Abstract | ||
| Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease marked by the loss of immune tolerance to nuclear antigens, predominantly affecting women of reproductive age. Objective: This research aims to assess disease activity in SLE patients and serum concentrations of chemokine (CXCL10, SIGLEC-1) in relation to disease severity. Methodology: A case-control study was conducted on 100 SLE patients and 25 healthy controls between January 7 and April 5, 2025. Diagnosis was based on the 1997 ACR criteria, and disease activity was assessed using SLEDAI-2K. Serum CXCL-10 and SIGLEC-1 levels were measured using a sandwich ELISA. Results: CXCL-10 levels were significantly higher in SLE patients than in controls (p < 0.001), with severe cases showed the highest values (546.2 ± 170.0 pg/ml). Similarly, SIGLEC-1 expression was elevated in active SLE, with severe cases demonstrating the highest levels compared to mild–moderate disease (4.1 ± 2.3 vs. 2.9 ± 0.6 ng/ml, p < 0.01). Clinical manifestations according to SLEDAI revealed that mucocutaneous involvement (54%), musculoskeletal (48%), hematologic (42%), and renal involvement (38%). indicating that chemokine upregulation reflects both systemic immune activation and specific organ involvement. Conclusion: Increased serum levels of CXCL-10 and SIGLEC-1, especially in severe SLE, underscore their potential role as reliable biomarkers. Their Strong correlation with SLEDAI supports their role in assessing disease activity and monitoring progression. | ||
| Keywords | ||
| Systemic lupus erythematosus (SLE); Disease activity (SLEDAI-2K); CXCL-10; SIGLEC-1 | ||
|
Statistics Article View: 77 |
||
